Fenofibrate for patients with asymptomatic primary biliary cirrhosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

383

HTML

3805

Figures (1-3)

212

Tables (1-3)

222

Sum=4622

Mar 15, 2004 (publication date) through Dec 21, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Mar 15, 2004; 10(6): 894-898
Published online Mar 15, 2004. doi: 10.3748/wjg.v10.i6.894

Figure 1 Change in the serum alkaline phosphatase levels during fenofibrate treatment.

Figure 2 Change in antimitochondria antibody titers before and after fenofibrate treatment.

Figure 3 Possible mechanisms of action for fibrates on PBC.

Citation: Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10(6): 894-898
URL: https://www.wjgnet.com/1007-9327/full/v10/i6/894.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i6.894